Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride and dutasteride may not significantly impact meibomian gland function since these glands do not rely on DHT. Some users report dry eyes and other side effects from finasteride, but these may be influenced by other factors or medications.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

The user experienced significant hair regrowth using a daily capsule containing 1mg finasteride, 2.5mg minoxidil, and 10mg biotin, with noticeable results after 3-4 months. They reported a decrease in libido as a side effect and considered switching to minoxidil only, but were advised against it.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Hair loss treatments are being tested on mice, with methods like minoxidil and stem cell therapy showing promising results. However, human trials are still years away, leading to humorous frustration about mice benefiting first.

A user is experimenting with applying undiluted peppermint oil to their scalp daily to stimulate hair growth, based on a rat study where peppermint oil outperformed minoxidil. The user reports immediate hair thickening and increased scalp blood flow, while others in the conversation express skepticism, humor, and concern about the undiluted application.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

The user experienced significant hair regrowth and increased density after six months of using oral minoxidil and finasteride chewables, despite going through a secondary shedding phase. The only side effect mentioned was restlessness, and the user feels healthier overall.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The conversation discusses using GHK-Cu copper peptide from Bulk Naturals for hair loss, comparing its price and quality to Peptide Sciences. Concerns about the product's legitimacy are mentioned, but COA documents are available.

HairClone aims to rejuvenate miniaturizing hair follicles through follicle banking and cell expansion, with treatments potentially available in the UK by 2022. The process involves extracting, storing, and cloning hair follicles, but full regenerative treatments will take many years to develop.

OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

A user experienced a tingling sensation in their mouth after taking a cut finasteride pill, possibly due to inactive ingredients like mannitol or sodium lauryl sulfate. Tingling is not a common side effect or typical allergy sign, but monitoring for unusual reactions is advised.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

The user is seeking advice on sourcing finasteride, dutasteride, and minoxidil, as their doctors are unwilling to prescribe both finasteride/dutasteride and minoxidil simultaneously. They are also looking for sources of GHK-Cu and RU58841 in the USA, with suggestions including using services like Hims, ro.co, and Musely.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

Jericho1017 shared their hair regrowth results after nearly 3 years using 1mg finasteride and 10,000mcg biotin daily, with noticeable improvement after 1.5 years and no significant side effects except for watery semen. Some users suggested adding minoxidil and microneedling to improve results, but Jericho1017 is currently content with their progress and not looking to add more treatments.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.